News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6%Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key …
PDS Biotechnology reported a net loss of $17.1 million for the six months ended June 30, 2026, with cash and cash equivalents significantly reduced to $5.6 million from $26.7 million at year-end 2025. The company's management disclosed substantial doubt about its ability to continue …
This article is an earnings snapshot for XBiotech's Q2 performance. It is a placeholder without actual financial details, suggesting that the full earnings report would contain the relevant financial data.
AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …
XBiotech Inc. reported a Q2 2026 net loss of $6.7 million and a six-month net loss of $12.2 million, despite significantly reducing research and development and general and administrative expenses. The clinical-stage biopharmaceutical company does not anticipate generating revenue in 2026 and expects continued …
PDS Biotechnology reported a net loss of $9.8 million for Q2 2026 and had $5.6 million in cash at quarter-end. The company announced a strategic refocus to prioritize its tumor-targeted IL-12 program, PDS0301, and will discontinue internal investment in PDS0101, seeking external partnerships for …
HC Wainwright has lowered its Q3 2026 earnings forecast for Sana Biotechnology (NASDAQ:SANA) to a loss of $0.14 per share, anticipating continued losses through future fiscal years. Despite this, Sana's last quarterly loss of $0.13 per share exceeded analyst expectations. The stock currently holds …
PDS Biotechnology Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $9.8 million. The company also provided a clinical and corporate update, highlighting positive clinical data for PDS0301 in metastatic colorectal cancer and announcing a …
Krystal Biotech (KRYS) reported strong Q2 2026 earnings with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, leading to a significant year-to-date share price return. Despite a recent short-term decline, the company is trading below analyst price targets, and …
Wasatch Advisors LP has acquired 576,266 shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) worth approximately $12.4 million, bringing institutional ownership in the company to 99.17%. Despite a reported wider-than-expected quarterly loss, Adaptive Biotechnologies saw a 21.5% year-over-year revenue increase. The stock is trading near its …
Adaptive Biotechnologies' Chief Commercial Officer, MRD, Susan Bobulsky, sold 3,000 shares of common stock at $25.00 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on December 16, 2025. Following the sale, Bobulsky directly holds 396,989 …
Adaptive Biotechnologies (ADPT) stock appears fairly valued based on its discounted cash flow model, which places its intrinsic value close to its current share price. However, the stock looks expensive when evaluated using market multiples, particularly its P/S ratio, which is significantly higher than …
Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of …
Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high …
Oncolytics Biotech (NASDAQ:ONCY) reported a quarterly loss of $0.08 per share, missing analysts' consensus estimate of a $0.05 loss by $0.03. Despite the earnings miss, the stock rose 0.5% to $0.82, and institutional investors have been increasing their holdings. Analysts currently rate the stock …
Vir Biotechnology (VIR) reported significant financial improvements in Q2 2026, with $1.01 billion in cash and investments and $238.9 million in revenue, driven by a collaboration with Astellas. The company highlighted strong progress in its hepatitis delta program, with promising clinical trial results for …
Oncolytics Biotech Inc. (ONCY) reported a widened net loss of $9.4 million in Q2 2026, attributed to rising R&D and G&A expenses due to clinical trial expansion and increased stock-based compensation. While current cash is sufficient for near-term milestones, the company will require additional …
Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the …
Legend Biotech's shares experienced a decline following an Oppenheimer downgrade from Outperform to Perform, citing potential pressures from competition and a CEO transition. Despite this, RBC maintained an Outperform rating for Legend Biotech, adjusting its price target slightly, due to positive outlooks on Carvykti …
Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate …
Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform following the resignation of its CEO, competitive pressures, and reduced M&A prospects. The analyst cited these factors as reasons for the downgrade. Legend Biotech's shares saw a decline on Wednesday after the announcement.
Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak …
RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …
Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …
(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …
Search by ticker symbol or company name and select a result to open its chart.